Dr. Toufan Parman is the Senior Director of Nonclinical Safety Evaluations at Sangamo Therapeutics where she is responsible for the management of Pharmacology, Toxicology, and Pharmacokinetic Programs. As the nonclinical lead, Dr. Parman provides preclinical drug development strategy and safety assessment expertise for various cell and gene therapy programs. She has produced seminal results and contributed both conceptually and technically to her fields of expertise, with over 30 peer reviewed publications, a patent, and several book chapters in high-ranking journals. Dr. Parman received her Ph.D. in Pharmaceutical Sciences from the University of Toronto, Canada specializing in mechanistic reproductive toxicology. She received Postdoctoral Fellowship awards from the Canadian Institutes of Health Research and the National Cancer Institute (NCI) to conduct postdoctoral training in the areas of cell signaling and cancer at the NCI, University of Arizona, and Stanford University. Prior to joining Sangamo, Dr. Parman worked at SRI International where she translated several novel male contraceptives, as well as small molecule drugs, biologic therapeutics, and vaccines for the treatment of infectious and neurodegenerative diseases, and cancer from discovery to clinical trials. Dr. Parman has been certified by the American Board of Toxicology since 2007.